// App-Quantinova.ai

5061 : IMAAGEN trial safety and efficacy update: Effect of abiraterone acetate and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Charles J. Ryan

Principal Investigators

  • E. David Crawford

  • Neal D. Shore

  • Willie Underwood

  • Mary-Ellen Taplin

  • Anil Londhe

  • Peter St. John Francis

  • Jennifer Phillips

  • Tracy McGowan

  • Philip W. Kantoff

Medical Centers

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • University of Colorado Cancer Center, Aurora, CO

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Roswell Park Cancer Institute, Buffalo, NY

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Janssen Research & Development, LLC, Horsham, PA

  • Janssen Scientific Affairs, Horsham, PA

Locations

  • United States

Companies

  • Janssen Global Servi

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Prednisone

Outcome

  • Indeterminate

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01314118

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved